Is Unichem Laboratories a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Unichem Laboratories Ltd is a below average quality company .

Is Unichem Laboratories undervalued or overvalued?

The key valuation ratios of Unichem Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Unichem Laboratories share price return in the past 10 years?

Unichem Laboratories Ltd share price has appreciated 13.5% annually (CAGR) over the past ten years.

Is Unichem Laboratories a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Unichem Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the P/E ratio of Unichem Laboratories?

The latest standalone P/E ratio of Unichem Laboratories as of 03-Dec-2024 is 312.51.

What is the P/B ratio of Unichem Laboratories?

The latest standalone P/B ratio of Unichem Laboratories as of 03-Dec-2024 is 2.54.

What is the 52-week high and low of Unichem Laboratories?

The 52-week high of Unichem Laboratories is Rs. 949.85 and the 52-week low is Rs. 401.10.

Unichem Laboratories Ltd - Stock Valuation and Financial Performance

Name: Unichem Laboratories
Brand: Unichem Laboratories

BSE: 506690 | NSE: UNICHEMLAB | Pharmaceuticals & Drugs | Small Cap

Place order

Unichem Lab Share Price

₹835.25 -16.35 -1.92%
as on 03-Dec'24 16:59

10 Year X-Ray of Unichem Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	9%	12.8%	-8.3%	-6.1%	-0.8%	-2.3%	2.5%	-3.1%	-10.2%	-3.4%	-
Value Creation Index ⓘ	-0.4	-0.1	-1.6	-1.4	-1.1	-1.2	-0.8	-1.2	-1.7	-1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	1,091	1,221	576	666	968	904	1,124	943	1,072	1,442	1,588
Sales YoY Gr.	-	11.9%	-52.8%	15.6%	45.3%	-6.5%	24.3%	-16.1%	13.7%	34.5%	-
Adj EPS ⓘ	7.1	11.9	-6.4	-17.8	0.9	-13.6	6.5	-9.5	-34.6	-9.6	2.7
YoY Gr.	-	67.5%	-153.6%	NA	NA	-1677.9%	NA	-244.9%	NA	NA	-
BVPS (₹) ⓘ	104.3	112.9	124.3	392.6	387.6	375.3	382	378	336.9	325.5	335.2
Adj Net Profit ⓘ	64.8	108	-58.2	-125	6	-95.5	45.9	-66.5	-243	-67.9	19
Cash Flow from Ops. ⓘ	88	117	141	-66.3	-251	-41.8	-32.6	-158	-117	-41.6	-
Debt/CF from Ops. ⓘ	0	0.1	0	-0	0	-0.4	0	-0.8	-0.9	-1.5	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	3.2%	8.3%	8.7%	34.5%
Adj EPS ⓘ	-203.4%	-262.2%	-213.9%	NA
BVPSⓘ	13.5%	-3.4%	-5.2%	-3.4%
Share Price	13.5%	38.4%	48.3%	99.6%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	7	11	-5.4	-6.4	0.2	-3.6	1.7	-2.5	-9.6	-2.9	0.8
Op. Profit Mgn % ⓘ	9.7	13.5	-5.4	-19.1	-5	-9.9	8.5	-4	-8.7	3.5	9.7
Net Profit Mgn % ⓘ	5.9	8.9	-10.1	-18.8	0.6	-10.6	4.1	-7.1	-22.7	-4.7	1.2
Debt to Equity ⓘ	0	0	0	0	0	0	0	0.1	0	0	0
Working Cap Days ⓘ	183	173	419	371	298	385	344	444	421	342	157
Cash Conv. Cycle ⓘ	71	63	181	152	122	175	154	245	243	191	101

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 0.80%

Sales growth is good in last 4 quarters at 28.98%

Sales growth has been subdued in last 3 years 8.66%

Latest Financials - Unichem Laboratories Ltd.

	Standalone	Consolidated
TTM EPS (₹)	2.7	-0.8
TTM Sales (₹ Cr.)	1,588	1,775
BVPS (₹.) ⓘ	335.2	341
Reserves (₹ Cr.) ⓘ	2,346	2,387
P/BV ⓘ	2.54	2.50
PE ⓘ	312.51	0.00

From the Market
52 Week Low / High (₹)	401.10 / 949.85
All Time Low / High (₹)	1.50 / 949.85
Market Cap (₹ Cr.)	5,996
Equity (₹ Cr.)	14.1
Face Value (₹)	2
Industry PE ⓘ	44.7

Management X-Ray of Unichem Lab:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Unichem Lab

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Unichem Lab

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	1,091	1,221	576	666	968	904	1,124	943	1,072	1,442
Operating Expenses ⓘ	990	1,078	634	802	1,029	995	1,029	986	1,165	1,391
Manufacturing Costs	168	170	131	164	306	293	276	266	290	329
Material Costs	375	396	188	275	339	311	359	325	455	592
Employee Cost	178	210	118	147	177	205	234	251	271	283
Other Costs ⓘ	268	303	197	217	207	186	160	145	149	187
Operating Profit ⓘ	101	142	-58	-136	-61	-91	95	-44	-93	51
Operating Profit Margin (%)	9.3%	11.7%	-10.1%	-20.5%	-6.3%	-10.0%	8.5%	-4.6%	-8.7%	3.5%
Other Income ⓘ	20	23	7	63	102	99	47	42	42	30
Interest ⓘ	2	2	2	3	1	1	1	2	9	10
Depreciation ⓘ	38	35	39	45	62	71	76	83	106	105
Exceptional Items ⓘ	0	-4	0	0	0	0	0	0	-113	-58
Profit Before Tax ⓘ	81	124	-92	-122	-22	-64	66	-87	-279	-92
Tax ⓘ	17	24	-17	0	-29	-7	12	-31	21	0
Profit After Tax	64	100	-76	-121	7	-56	54	-55	-300	-92
PAT Margin (%)	5.9%	8.2%	-13.1%	-18.2%	0.7%	-6.2%	4.8%	-5.9%	-27.9%	-6.4%
Adjusted EPS (₹)	7.1	11.1	-8.3	-17.3	1.0	-8.0	7.7	-7.9	-42.6	-13.1
Dividend Payout Ratio (%)	28%	18%	-36%	-29%	400%	-50%	52%	-51%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	947	1,026	1,129	2,761	2,728	2,642	2,690	2,661	2,372	2,292
Share Capital ⓘ	18	18	18	14	14	14	14	14	14	14
Reserves ⓘ	928	1,008	1,111	2,747	2,714	2,628	2,676	2,647	2,358	2,277
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	0	8	1	0	0	15	0	100	76	38
Long Term Debt	0	0	0	0	0	0	0	89	64	38
Short Term Debt	0	8	1	0	0	15	0	11	12	0
Trade Payables	143	190	228	212	193	208	189	157	244	249
Others Liabilities ⓘ	132	149	144	135	109	159	241	203	193	284
Total Liabilities ⓘ	1,222	1,373	1,503	3,108	3,030	3,025	3,119	3,122	2,886	2,864
Fixed Assets
Gross Block	684	415	536	655	939	1,038	1,128	1,324	1,691	1,718
Accumulated Depreciation	288	33	71	104	154	213	282	360	455	553
Net Fixed Assetsⓘ	396	381	464	551	785	825	846	963	1,236	1,165
CWIP ⓘ	119	233	247	236	90	331	568	494	148	122
Investmentsⓘ	153	111	89	979	1,042	668	520	390	41	44
Inventories	186	201	254	208	274	316	386	461	480	501
Trade Receivables	206	265	296	232	331	323	360	381	472	558
Cash Equivalents	20	11	10	674	191	205	58	99	157	129
Others Assetsⓘ	142	173	142	229	316	357	380	334	352	344
Total Assets ⓘ	1,222	1,373	1,503	3,108	3,030	3,025	3,119	3,122	2,886	2,864

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	88	117	141	-66	-251	-42	-33	-158	-117	-42
PBT ⓘ	81	124	132	3,249	-19	-64	66	-87	-279	-92
Adjustment ⓘ	36	56	72	-3,214	-7	-6	50	72	203	165
Changes in Working Capital ⓘ	-12	-33	-36	-103	-218	25	-148	-148	-41	-115
Tax Paid ⓘ	-18	-31	-27	2	-7	3	0	4	0	0
Cash Flow From Investing Activity ⓘ	-62	-87	-132	1,648	-323	-36	-80	106	202	53
Capex	-76	-134	-142	-153	-189	-377	-285	-126	-36	-11
Net Investments	-29	27	1	2,480	-147	296	187	204	237	65
Others ⓘ	44	20	9	-679	14	45	18	29	2	-1
Cash Flow From Financing Activityⓘ	-47	-39	-9	-930	-45	-21	-45	96	-62	-48
Net Proceeds from Shares ⓘ	1	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	-10	-26	-26
Interest Paid ⓘ	-2	-2	-2	-3	-2	-1	-1	-2	-9	-10
Dividend Paid ⓘ	-36	-43	-1	-33	-42	-34	-29	-28	-28	0
Others ⓘ	-10	6	-7	-894	0	14	-15	135	1	-13
Net Cash Flow ⓘ	-21	-9	0	653	-619	-98	-158	44	23	-36

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	6.95	10.19	-7.01	-6.24	0.26	-2.1	2.03	-2.07	-11.91	-3.95
ROCE (%)	9.04	12.75	-8.33	-6.08	-0.76	-2.32	2.5	-3.08	-10.21	-3.38
Asset Turnover Ratio	0.91	0.95	0.4	0.29	0.32	0.3	0.37	0.3	0.36	0.5
PAT to CFO Conversion(x)	1.38	1.17	N/A	N/A	-35.86	N/A	-0.61	N/A	N/A	N/A
Working Capital Days
Receivable Days	69	70	178	145	106	132	111	143	145	130
Inventory Days	62	57	144	126	91	119	114	164	160	124
Payable Days	143	153	406	292	217	235	202	194	161	152

Unichem Laboratories Ltd Stock News

Unichem Laboratories Ltd FAQs

What is the share price of Unichem Lab?

Company share prices are keep on changing according to the market conditions. The closing price of Unichem Lab on 03-Dec-2024 16:59 is ₹835.2.

What is the market cap of Unichem Lab?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Dec-2024 16:59 the market cap of Unichem Lab stood at ₹5,995.8.

What is the P/E ratio of Unichem Lab?

The latest P/E ratio of Unichem Lab as of 03-Dec-2024 16:59 is 312.5.

What is the P/B ratio of Unichem Lab?

The latest P/B ratio of Unichem Lab as of 03-Dec-2024 16:59 is 2.54.

What is the 52-week high and low of Unichem Lab?

The 52-week high of Unichem Lab is ₹949.9 and the 52-week low is ₹401.1.

What is the TTM revenue of Unichem Lab?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Unichem Lab is ₹1,588 ( Cr.) .

About Unichem Laboratories Ltd

Unichem Laboratories, incorporated in 1962, is engaged in manufacturing formulations, pharmaceuticals and active pharmaceutical ingredients (APIs). The company was promoted by the late Amrut Mody, a pioneer in the Indian pharmaceuticals business.

The company offers products in therapeutic areas like gastro-intestinal, cardiovascular, diabetes, psychiatry, neurology, anti-bacterial, anti-infective and pain management, among others.

Headquartered in Mumbai, the company operates at five manufacturing locations in Roha (Maharashtra), Goa, Ghaziabad (Uttar Pradesh), Pithampur (Madhya Pradesh) and Baddi (Himachal Pradesh).

The companyâ€™s manufacturing facilities have received approval from various international agencies namely UK MHRA, MCC (South Africa), WHO (Geneva) and TGA (Australia). The manufacturing plants have also received ISO 9001:2000 and ISO 14001:2004 certifications for quality management.

Unichem also operates a research and development facility located at Jogeshwari (Mumbai). This facility conducts research in area of Novel Drug Delivery Systems (NDDS) and develops non-infringing routes for the manufacture of products directed at the regulated markets.

Milestones

1944- Unichem was commissioned by Late Amrut Mody.

1952- The company forayed into exporting activities.

1953- Unichem entered into hormonal products segment. The same year it launched UNIPROGESTIN.

1962- The company collaborated with foreign entity UCB for bulk-drugs. It set up its first formulation plant at Jogeshwari. The company got listed at Bombay Stock Exchange. Unichem launched OESTROGEN and Progestin.

1963- The company entered co-marketing of formulations tie up with Uni Sankyo.

1968- Unichem set up a formulation plant at Ghaziabad.

1970- As part of back integration strategy, the company commissioned manufacturing of Anti-TB Drugs.

1972- As an acknowledgement for Late Amrut Modyâ€™s pioneering effort in Indian pharma industry, he was awarded Padma Bhushan.

1973- Unichem's research laboratory was recognised for Phd work by Bombay University. Unichem's R&D centre was recognised by Department of Science and Technology.

1976- The company set up a fine chemicals unit at Roha.

1978- Unichem commissioned its Roha bulk drug plant.

1979- The company received its first clearance from drug authorities for NEFEDIFINE.

1983- Unichem received the USFDA approval for hydrochlorothiazide manufactured at the Jogeshwari plant. The company introduced Anti-TB - Isoniazid, Rifampicin in white tablet form for the first time in India.

1984- UNISEARCH was established in collaboration with Upjohn. The company forayed anti-biotic segment and launched Ampoxin (Ampicillin and Cloxacillin combination).

1987- The company entered the animal health care business.

1994-1999- Unichem underwent thorough restructuring and transformation in line with future growth strategies.

1996- Two companies namely Unichem Exports and Unisearch was merged with Unichem Laboratories.

1997- The companyâ€™s formulation plant located at Goa was commissioned. It set up new corporate office set up at Unichem Bhavan Jogeshwari, Mumbai.

1998- The companyâ€™s formulations plant located at Baddi was fully operational.

1997-2000- The company implemented BaaN ERP.

1999- Unichem set up a modern multipurpose bulk drug plant located at Roha. Molecular generics division was launched.

2000- The drug major received South African Health Authority and UK MCA (MHRA) certifications for Goa and Baddi Plants

2001- Unichem set up new research and development centre at Mumbai. The same year it also set up New Biosciences R&D Centre located at Bangalore that would conduct research work in Bio-technology

2002- It formed a joint venture in UK called Niche Generics.

2002-2003- The company divested its animal healthcare division. It established subsidiaries in South Africa and Brazil. The company also undertook modernization of formulations plant located at Ghaziabad.

2004- Unichem conducted restructuring of Unisearch and launched of Unisearch CD Division.

2005- The company set up of new pharma technology development center located at Goa. Unichem Baddi Unit II plant was commissioned. It acquired API manufacturing unit at Pithampur

2006- The company received USFDA certification for the Goa Plant. It launched specialities division. In the same year it acquired 100% stake in Niche Generics, United Kingdom.

2007- Unikare division launched that catered to Dermatology and Allied therapies segment.

Future Strategies

Unichem will continue to work on the therapeutic segments and will develop cost effective processes for the existing molecules. It will also focus on develop new drug delivery systems and new products for international business.